New three-year follow-up results from the TRANSCEND FL trial show that patients with relapsed or refractory follicular lymphoma can achieve durable, multi-year remission with chimeric antigen receptor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback